One of the key insights from the study is the wide diversity among MS patients and the need for extensive cohort characterization in the real-world scenario. Drugs for first-line treatment were most frequently used, followed by high-efficacy drugs. The relative frequencies of use of first-line and second-line treatment changed significantly with time since diagnosis. The study also identified the top five symptoms affecting users, thereby providing valuable insights from the patient's perspective.
Balakrishnan, P., Groenberg, J., Jacyshyn-Owen, E., Eberl, M., Friedrich, B., Joschko, N., & Ziemssen, T. (2022). Demographic patterns of MS patients using BRISA: An MS-specific app in Germany. Journal of Personalized Medicine, 12(7), 1100.
